Last reviewed · How we verify
NCT07239609: ACT
ACT for Individuals With MNCD and Their Care Partners
Phase 1 trial testing Acceptance Commitment Therapy in Depression in Adults in 100 participants. Not yet recruiting.
31 October 2027
Quick facts
| Lead sponsor | Texas Tech University |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 January 2026 |
| Primary completion | 31 October 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Acceptance Commitment Therapy
Conditions studied
- Depression in Adults — all drugs for Depression in Adults →
- Anxiety Disorder Generalized — all drugs for Anxiety Disorder Generalized →
- Grief — all drugs for Grief →
Sponsor
Texas Tech University
Who can join
18 and older, any sex, with Depression in Adults or Anxiety Disorder Generalized. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07239609
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acceptance Commitment Therapy
Trials testing the same drug.
- NCT05334914 — ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals · NA · unknown
- NCT05364450 — Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors · NA · completed
Other recruiting trials for Depression in Adults
Currently open trials in the same condition.
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07493369 — Positive Affect Treatment for Spanish-Speaking Individuals · NA · active not recruiting
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT06793397 — A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder · Phase 3 · recruiting
Other Texas Tech University trials
Trials by the same sponsor.
- NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
- NCT06919536 — Controlled Feeding With 24 Hour Recall · completed
- NCT06055322 — Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD · NA · recruiting
- NCT06865196 — Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17 · NA · active not recruiting
- NCT06334107 — Mitochondrial DNA Signatures of Poor Aerobic Exercise Trainability in Young Adults Born Preterm · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07239609 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Tech University
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07239609.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing